Journal article

Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction - A double-blind, randomized angiographic trial of lanoteplase versus alteplase

P den Heijer, F Vermeer, E Ambrosioni, Z Sadowski, JL Lopez-Sendon, R von Essen, P Beaufils, U Thadani, J Adgey, L Pierard, J Brinker, RF Davies, RW Smalling, L Wallentin, A Caspi, A Pangerl, L Trickett, C Hauck, D Henry, P Chew

CIRCULATION | LIPPINCOTT WILLIAMS & WILKINS | Published : 1998

Abstract

BACKGROUND: Lanoteplase (nPA) is a rationally designed variant of tissue plasminogen activator with greater fibrinolytic potency and slower plasma clearance than alteplase. METHODS AND RESULTS: InTIME (Intravenous nPA for Treatment of Infarcting Myocardium Early), a multicenter, double-blind, randomized, double-placebo angiographic trial, evaluated the dose-response relationship and safety of single-bolus, weight-adjusted lanoteplase. Patients (n=602) presenting within 6 hours of acute myocardial infarction were randomized and treated with either a single-bolus injection of lanoteplase (15, 30, 60, or 120 kU/kg) or accelerated alteplase. The primary objective was to determine TIMI grade flow..

View full abstract